{
    "name": "calaspargase pegol",
    "comment": "Rx",
    "other_names": [
        "Asparlas",
        "calaspargase pegol-mknl"
    ],
    "classes": [
        "Enzymes",
        "Oncology"
    ],
    "source": "https://reference.medscape.com/drug/asparlas-calaspargase-pegol-1000267",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Based on studies in pregnant animals, calaspargase pegol can cause fetal harm when administered to pregnant women",
            "Conduct pregnancy testing in females of reproductive potential before initiating treatment"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Published literature studies in pregnant animals suggest asparagine depletion may cause harm to the animal offspring; advise patients of the potential risk to a fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to avoid becoming pregnant while receiving calaspargase pegol",
                    "Effective contraceptive methods, including a barrier method, should be used during treatment and for at least 3 months after the last dose",
                    "Since there is a potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use is not recommended",
                    "Advise females of reproductive potential to use effective non-hormonal contraceptive methods during treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of calaspargase pegol in human milk, the effects on the breastfed child, or the effects on milk production",
            "Because many drugs are excreted in human milk and because of the potential for adverse reactions in a breastfed child, advise lactating women not to breastfeed while receiving calaspargase pegol and for 3 months after the last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase",
                "History of serious thrombosis, pancreatitis, or hemorrhagic during previous L-asparaginase therapy",
                "Severe hepatic impairment"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Also see Dosage Modifications",
                "Pancreatitis reported; inform patients of signs and symptoms, which, if untreated, could be fatal; assess serum amylase and/or lipase levels; discontinue if pancreatitis suspected and permanently discontinue if confirmed",
                "Serious thrombotic events, including sagittal sinus thrombosis, reported; discontinue if thrombotic event occurs",
                "Hemorrhage associated with increased PT, PTT, and hypofibrinogenemia reported; consider appropriate replacement therapy with severe or symptomatic coagulopathy"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Premedicate patients 30-60 min prior to administration of therapy",
                        "Grade 3-4 hypersensitivity, including anaphylaxis, reported",
                        "Symptoms may include angioedema, lip swelling, eye swelling, erythema, decreased blood pressure, bronchospasm, dyspnea, pruritus, or rash",
                        "Because of this risk, administer in clinical setting with resuscitation equipment and other agents necessary to treat anaphylaxis (eg, epinephrine, oxygen, intravenous steroids, antihistamines) and observe patients for 1 hr after administration",
                        "Discontinue with serious hypersensitivity"
                    ]
                },
                {
                    "type": "Hepatoxicity",
                    "description": [
                        "Hepatotoxicity and abnormal liver function, including elevated transaminases, bilirubin, reduced serum albumin, and plasma, can occur",
                        "Evaluate bilirubin and transaminases at least weekly during treatment cycles and through at least 6 weeks after last dose",
                        "Discontinue if serious liver toxicity occurs; provide supportive care"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "calaspargase pegol, dienogest/estradiol valerate. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "drospirenone",
            "description": {
                "common": "calaspargase pegol, drospirenone. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "calaspargase pegol, ethinylestradiol. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral",
            "description": {
                "common": "calaspargase pegol, levonorgestrel oral. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "calaspargase pegol, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pancreatitis",
            "percent": "12-16"
        },
        {
            "name": "Thrombotic events",
            "percent": "9-12"
        },
        {
            "name": "Elevated transaminase",
            "percent": "52"
        },
        {
            "name": "Hypersensitivity",
            "percent": "7-21"
        },
        {
            "name": "Increased bilirubin",
            "percent": "20"
        },
        {
            "name": "Pancreatitis",
            "percent": "18"
        },
        {
            "name": "Abnormal clotting studies",
            "percent": "14"
        },
        {
            "name": "Diarrhea",
            "percent": "9"
        },
        {
            "name": "Embolic and thrombotic events",
            "percent": "8"
        },
        {
            "name": "Sepsis",
            "percent": "5"
        },
        {
            "name": "Dyspnea",
            "percent": "4"
        },
        {
            "name": "Hemorrhages",
            "percent": "4"
        },
        {
            "name": "Fungal infection",
            "percent": "3"
        },
        {
            "name": "Pneumonia",
            "percent": "3"
        },
        {
            "name": "Arrhythmia",
            "percent": "2"
        },
        {
            "name": "Cardiac failure",
            "percent": "2"
        }
    ]
}